GlassScriptPhysician profile
Stephen W Doggett
NPI 1982675021
$33,004.39
in general payments reported to CMS, 2019-2025
42 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $1,046 · 2021: $616 · 2022: $608 · 2023: $1,071 · 2024: $141 · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Travel and Lodging: $7,619 · Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,700.00 |
| Travel and Lodging | $7,619.05 |
| Food and Beverage | $1,018.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $29,036.35 | 2025 | Elekta Medical Linear Accelerator, Flexitron Hdr |
| Isoray, INC | $1,980.02 | 2019-2023 | Brachytherapy Source |
| Janssen Biotech, INC. | $327.67 | 2021-2025 | Darzalex, Imbruvica, Tecvayli |
| Amgen INC. | $144.18 | 2019-2021 | |
| Ethicon INC. | $107.27 | 2022 | |
| Karyopharm Therapeutics INC. | $93.03 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.01 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $84.27 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $81.34 | 2019-2021 | |
| Lilly USA, LLC | $77.85 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.80 | 2021-2023 | Alunbrig |
| Genzyme Corporation | $63.56 | 2020-2023 | |
| Boston Scientific Corporation | $58.46 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Seagen INC. | $54.94 | 2020-2022 | |
| Siemens Medical Solutions USA, INC. | $47.96 | 2023 | Bravos Afterloader System |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Doggett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.